AIF-1

AIF-1 is a novel synthetic compound that functions as an inhibitor of ATP-binding cassette B1 (ABCB1), also known as P-glycoprotein (P-gp) or multidrug resistance 1 (MDR1). It is being developed to overcome multidrug resistance in cancer treatment. By inhibiting ABCB1, AIF-1 prevents the efflux of chemotherapeutic drugs, such as doxorubicin, from cancer cells, thereby increasing their intracellular concentration and enhancing their cytotoxic effects. Preclinical studies have shown that AIF-1 significantly inhibits ABCB1 activity and increases doxorubicin content in non-small cell lung cancer (NSCLC) cells, leading to reduced cellular proliferation. In murine xenograft models, co-administration of AIF-1 with doxorubicin significantly reduced tumor volume compared to doxorubicin alone. The University of Parma is involved in its initial development.